Pharma Focus America

Immutep Signs Exclusive Agreement with Cardiff University for Next-Generation Anti-LAG-3 Molecules in Cancer Therapy

Wednesday, June 26, 2024

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced a License Agreement with Cardiff University granting exclusive rights to develop and commercialize small molecule anti-LAG-3 therapies for cancer and autoimmune diseases. LAG-3 is an immune checkpoint that suppresses the immune response against cancer cells.

Immutep collaborated with Cardiff University to identify promising small molecules through chemical screening, molecular modeling, and synthetic chemistry. These compounds, developed with leading scientists including Professors Andrew Godkin and Andrea Brancale, offer potential advantages in convenience and cost-effectiveness over existing therapies, as they can be administered orally.

Dr. Frédéric Triebel, Immutep's Chief Scientific Officer, emphasized the strategic importance of this agreement, aligning with Immutep's ongoing efforts in LAG-3 therapeutics. The company's portfolio includes eftilagimod alfa, a leading MHC Class II agonist in late-stage clinical trials for oncology, and IMP761, the first LAG-3 agonist antibody targeting autoimmune diseases, set to enter clinical trials soon.

To protect these innovations, Immutep and Cardiff University have jointly filed a patent application. The agreement includes an upfront payment and potential future milestone and royalty payments to Cardiff University, reflecting the collaborative nature of the partnership.

This development underscores Immutep's commitment to advancing novel therapies in cancer immunotherapy and autoimmune disease treatment.



Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024